Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein

Michael H. Davidson, Nicola Abate, Christie M. Ballantyne, Alberico L. Catapano, Xia Xu, Jianxin Lin, Elizabeth Rosenberg, Andrew M. Tershakovec

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Recent evidence suggests that in addition to low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo-B), non-high-density lipoprotein cholesterol (non-HDL-C), some lipoprotein ratios, and C-reactive protein (CRP) are predictive of coronary heart disease (CHD) risk. This post-hoc analysis of two trials comparing single-tablet ezetimibe/simvastatin (EZE/SIMVA) to atorvastatin (ATORVA) or rosuvastatin (ROSUVA) evaluates the proportion of patients attaining LDL-C

Original languageEnglish
Pages (from-to)436-446
Number of pages11
JournalJournal of Clinical Lipidology
Volume2
Issue number6
DOIs
Publication statusPublished - Dec 2008

Keywords

  • Atorvastatin
  • Coronary heart disease: Ezetimibe
  • Hypercholesterolemia
  • Rosuvastatin
  • Simvastatin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics

Fingerprint

Dive into the research topics of 'Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein'. Together they form a unique fingerprint.

Cite this